M
Maat Pharma SA
PAR:MAAT
Maat Pharma SA
PAR:MAAT
Price:
6.64
EUR
-7.52%
Market Closed
Market Cap:
€125m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
M
|
Maat Pharma SA
PAR:MAAT
|
FR |
|
F
|
Fenix Entertainment SpA
MIL:FNX
|
IT |
|
Dynasil Corporation of America
OTC:DYSL
|
US |
|
United Bancshares Inc
OTC:UBOH
|
US |
|
Z
|
Zhongrun Resources Investment Corp
SZSE:000506
|
CN |
|
Wescan Goldfields Inc
XTSX:WGF
|
CA |
|
N
|
NZME Ltd
ASX:NZM
|
NZ |
|
Gudang Garam Tbk PT
IDX:GGRM
|
ID |
|
O
|
Overactive Media Corp
XTSX:OAM
|
CA |
|
Investment AB Latour
OTC:IVTBF
|
SE |
|
Okta Inc
NASDAQ:OKTA
|
US |
|
L
|
Linkage Software Co Ltd
SSE:688588
|
CN |
|
Grinm Advanced Materials Co Ltd
SSE:600206
|
CN |
|
Abacus Mining and Exploration Corp
XTSX:AME
|
CA |
Balance Sheet
Balance Sheet Decomposition
Maat Pharma SA
Maat Pharma SA
Balance Sheet Decomposition is not available for
Maat Pharma SA
Maat Pharma SA
Balance Sheet
Maat Pharma SA
Maat Pharma SA
Currency: EUR
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
4
|
5
|
20
|
43
|
35
|
24
|
20
|
|
| Cash |
4
|
5
|
20
|
43
|
17
|
5
|
11
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
19
|
19
|
9
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
2
|
3
|
5
|
5
|
6
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
3
|
4
|
5
|
5
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
1
|
2
|
2
|
1
|
|
| Total Current Assets |
5
|
7
|
22
|
47
|
42
|
32
|
28
|
|
| PP&E Net |
0
|
0
|
1
|
1
|
1
|
9
|
9
|
|
| PP&E Gross |
0
|
0
|
1
|
1
|
1
|
9
|
9
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
1
|
2
|
3
|
|
| Intangible Assets |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
6
N/A
|
8
+39%
|
24
+197%
|
49
+104%
|
45
-9%
|
43
-4%
|
39
-10%
|
|
| Liabilities | ||||||||
| Accounts Payable |
1
|
2
|
1
|
2
|
5
|
6
|
9
|
|
| Accrued Liabilities |
0
|
0
|
1
|
1
|
1
|
1
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
1
|
1
|
3
|
3
|
3
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Current Liabilities |
2
|
3
|
3
|
5
|
9
|
12
|
15
|
|
| Long-Term Debt |
2
|
10
|
5
|
5
|
8
|
11
|
13
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Liabilities |
5
N/A
|
13
+176%
|
8
-35%
|
10
+15%
|
18
+87%
|
22
+25%
|
28
+25%
|
|
| Equity | ||||||||
| Common Stock |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Retained Earnings |
11
|
5
|
5
|
8
|
13
|
18
|
27
|
|
| Additional Paid In Capital |
12
|
0
|
20
|
46
|
38
|
37
|
35
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
5
N/A
|
16
N/A
|
40
+150%
|
27
-33%
|
20
-24%
|
10
-49%
|
|
| Total Liabilities & Equity |
6
N/A
|
8
+39%
|
24
+197%
|
49
+104%
|
45
-9%
|
43
-4%
|
39
-10%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
10
|
10
|
10
|
10
|
10
|
12
|
14
|
|
Switch to:
Switch to:
See Also
Discover More
